10 Best Hep C Treatment Centers
Although criteria for determining which medical institutions made this list are not included, these 10 Hepatitis C treatment centers are touted as the best nationwide.
Continue reading »Research & Treatment News
Share
Follow Us
Strong Hepatitis C Cocktail Contenders
Two of Gilead's investigational drugs, GS 9190 and GS 9256, showed high HCV viral suppression rates - especially when combined with ribavirin and pegylated interferon.
Continue reading »Hepatitis C Interim Study Results Favorable for TMC435
In combination with pegylated interferon and ribavirin, Tibotec and Medivir's TMC435 showed high antiviral activity and tolerability in a Phase 2b Hepatitis C study.
Continue reading »Coming Soon: A Multi-Drug Cocktail for Hepatitis C
Similar to how AIDS is now treated, pharmaceutical and biotech companies are racing to come up with the optimal oral combination of drugs that can safely suppress Hepatitis C.
Continue reading »Locteron Triumphs in Phase 2 Hepatitis C Trial
With dosing once every other week, a similar effectiveness as PEG-Intron and fewer side effects, Locteron's Phase 2B trial is successful.
Continue reading »Human Cells in Mice Provide New Model for Studying HCV
By engineering mice livers to contain enough human cells, researchers at the Salk Institute for Biological Studies are making progress in the quest to find better therapeutic solutions for many ailments, including Hepatitis C.
Continue reading »New Study Finds Hepatitis C Capable of Hurting Brain Cells
Helping to bring a new level of understanding to the Hepatitis C virus (HCV), a University of Alberta study found that this infection can affect neural cells. Besides helping explain some common Hepatitis C symptoms, these findings could pave the way for a new frontier in HCV treatment.
Continue reading »Why Hepatitis C Patients Should Practice Diabetes Prevention
November is National Diabetes Awareness Month. By analyzing relevant research, it appears that diabetes prevention efforts may protect Hepatitis C previous non-responders from developing liver cancer.
Continue reading »Nitazoxanide and IC41 Take on Interferon and Ribavirin
Intercell's investigational, therapeutic Hepatitis C vaccine, IC41, and Romark's antiviral drug, nitazoxanide, will be studied together to see if their effectiveness at fighting Hepatitis C can top the current standard of treatment - pegylated interferon and ribavirin.
Continue reading »Unique Oral Drug Combo Acknowledged as Potential Hepatitis C Therapy
A small study found that combining two oral drugs (not including interferon or ribavirin) demonstrated potential in treating Hepatitis C without many serious adverse events.
Continue reading »
